Q-Line Biotech (NSE:QLINE) EV-to-EBIT: (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
14 GF Score
Price ₹531.80
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Q-Line Biotech's Enterprise Value is ₹14,831 Mil. Q-Line Biotech does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Q-Line Biotech's EV-to-EBIT at this moment.

The historical rank and industry rank for Q-Line Biotech's EV-to-EBIT or its related term are showing as below:

NSE:QLINE' s EV-to-EBIT Range Over the Past 10 Years
Min: 22.15   Med: 24.75   Max: 26.14
Current: 25.8

During the past 3 years, the highest EV-to-EBIT of Q-Line Biotech was 26.14. The lowest was 22.15. And the median was 24.75.

NSE:QLINE's EV-to-EBIT is ranked worse than
64.97% of 471 companies
in the Medical Devices & Instruments industry
Industry Median: 19.17 vs NSE:QLINE: 25.80

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Q-Line Biotech's Enterprise Value for the quarter that ended in Mar. 2025 was ₹0 Mil. Q-Line Biotech does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Q-Line Biotech's Earnings Yield (Joel Greenblatt) % at this moment.

Q-Line Biotech  (NSE:QLINE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Q-Line Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=/0
= %

Q-Line Biotech EV-to-EBIT Related Terms

Q-Line Biotech EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech EV-to-EBIT Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
EV-to-EBIT
0.00 0.00 0.00

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
EV-to-EBIT 0.00 0.00 0.00

NSE:QLINE vs ABT, SYK, MDT: EV-to-EBIT Comparison

For the Medical Devices subindustry, Q-Line Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q-Line Biotech EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Q-Line Biotech's EV-to-EBIT falls into.


NSE:QLINE
14GF Score
Q-Line Biotech Ltd NSE:QLINE
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech EV-to-EBIT Calculation

Q-Line Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=14830.817/
=

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score

Get the complete analysis for NSE:QLINE

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹531.80
Price